var data={"title":"Megestrol acetate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Megestrol acetate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6522?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=megestrol-acetate-drug-information\" class=\"drug drug_general\">see &quot;Megestrol acetate: Drug information&quot;</a> and <a href=\"topic.htm?path=megestrol-acetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Megestrol acetate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192314\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Megace ES;</li>\n      <li>Megace Oral [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192315\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Megace OS;</li>\n      <li>Megestrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060125\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Progestin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060118\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=megestrol-acetate-drug-information\" class=\"drug drug_general\">see &quot;Megestrol acetate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Megace ES is not equivalent mg per mg with other megestrol formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Appetite stimulant/anorexia associated with chronic illness (eg, cancer, cystic fibrosis, HIV)</b>: Limited data available: Infants &ge;8 months, Children, and Adolescents: Oral: Tablets or 40 mg/mL suspension: Initial dose: 7.5 to 10 mg/kg/day in 1 to 2 divided doses; titrate dose to response, decrease dose if weight gain is excessive. Reported duration was 3 to 11 months. Maximum daily dose: 800 mg/<b>day</b> or 15 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing based on several prospective and retrospective trials and case series. Clinical trials show benefit for weight gain and body mass (Azcona 1996; Brady 1994; Clarick 1997; Cuvelier 2014; Eubanks 2002; Hobbs 2010; Marchand 2000; Nasr 1999; Orme 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anorexia or cachexia associated with AIDS:</b> Oral: Suspension: Initial: 625 mg daily (of the 125 mg/mL suspension) or 800 mg daily (of the 40 mg/mL suspension); daily doses of 400 mg to 800 mg have been found to be effective</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, advanced</b>: Oral: Tablet: 40 mg 4 times daily for at least 2 months</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <b>Endometrial cancer, advanced</b>: Females: Oral: Tablet: 40 to 320 mg daily in divided doses for at least 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the urinary excretion of megestrol acetate is substantial, use caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192294\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Megace ES: 625 mg/5 mL (150 mL) [contains alcohol, usp, sodium benzoate; lemon-lime flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Megace Oral: 40 mg/mL (240 mL [DSC]) [lemon-lime flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/mL (10 mL, 240 mL, 480 mL); 400 mg/10 mL (10 mL); 625 mg/5 mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060128\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Megace 40 mg/mL: Shake oral suspension well before administering; the effect of food on the bioavailability of MEGACE Oral Suspension has not been evaluated; Megase ES: May administer without regard to food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132799\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192309\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from heat. Store/dispense in a tight container.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light. Protect from temperatures above 40&deg;C (104&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060127\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Treatment of anorexia; cachexia; or an unexplained, significant weight loss in patients with AIDS (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note</b>: Treatment of AIDS-related weight loss should only be initiated after addressing the treatable causes for weight loss (eg, malignancy, infection, malabsorption, endocrine disease, renal disease, psychiatric disorder). Megestrol is not intended to prevent weight loss.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Treatment (palliative) of advanced breast cancer and advanced endometrial carcinoma (FDA approved in adults); has also been used for the treatment of cachexia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192337\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Megace may be confused with Reglan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Megestrol may be confused with mesalamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Megestrol is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to an increased risk of thrombotic events and potentially death in older adults, with minimal effects on weight (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Megestrol is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192335\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac failure, cardiomyopathy, chest pain, edema, hypertension, palpitations, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Abnormality in thinking, carpal tunnel syndrome, confusion, convulsions, depression, headache, hypoesthesia, insomnia, lethargy, malaise, mood change, neuropathy, pain (similar to placebo), paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, dermatological disease, diaphoresis, pruritus, skin rash, vesicobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Adrenocortical insufficiency, albuminuria, amenorrhea, Cushing's syndrome, decreased libido, diabetes mellitus, gynecomastia, hot flash, HPA-axis suppression, hypercalcemia, hyperglycemia, increased lactate dehydrogenase, weight gain (not attributed to edema or fluid retention)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea (similar to placebo), dyspepsia, flatulence, nausea, oral moniliasis, sialorrhea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Breakthrough bleeding, impotence, urinary frequency, urinary incontinence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia, sarcoma, tumor flare</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatomegaly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Candidiasis, herpes virus infection, infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Amblyopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, dyspnea, hyperventilation, pharyngitis, pneumonia, pulmonary disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Decreased glucose tolerance, thromboembolic phenomena (including deep vein thrombosis, pulmonary embolism, thrombophlebitis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to megestrol or any component of the formulation; known or suspected pregnancy (suspension).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for progestins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192282\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May suppress hypothalamic-pituitary-adrenal (HPA) axis during chronic administration; consider the possibility of adrenal suppression in any patient receiving or being withdrawn from chronic therapy when signs/symptoms suggestive of hypoadrenalism are noted (during stress or in unstressed state). Laboratory evaluation and replacement/stress doses of rapid-acting glucocorticoid should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cushing syndrome: Has been reported with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS-related cachexia: The effects on HIV viral replications are unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: New-onset diabetes mellitus and exacerbation of preexisting diabetes have been reported with long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Use with caution in patients with a history of thromboembolic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females: Vaginal bleeding or discharge may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant drug interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concentrated suspension: Megace ES suspension in not equivalent to other formulations on a mg-per-mg basis; Megace ES suspension 625 mg/5 mL is equivalent to megestrol acetate suspension 800 mg/20 mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299657\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192287\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12578&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Megestrol may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192290\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (tablet) / X (suspension) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4627707\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were demonstrated in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Use during pregnancy is contraindicated (suspension) and appropriate contraception is recommended in women who may become pregnant. In clinical studies, megestrol was shown to cause breakthrough vaginal bleeding in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060124\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs of thromboembolic phenomena and adrenal axis suppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Appetite stimulation: Weight, caloric intake, basal cortisol level, serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antineoplastic: Tumor response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192281\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A synthetic progestin with antiestrogenic properties which disrupt the estrogen receptor cycle. Megestrol interferes with the normal estrogen cycle and results in a lower LH titer. May also have a direct effect on the endometrium. Megestrol is an antineoplastic progestin thought to act through an antileutenizing effect mediated via the pituitary. May stimulate appetite by antagonizing the metabolic effects of catabolic cytokines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192300\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Breast or endometrial cancer: At least 2 months of continuous therapy; Weight gain: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (to free steroids and glucuronide conjugates)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Suspension: 20 to 50 hours; Tablet: Mean: 34.2 hours (range: 13 to 105 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Suspension: 5 hours; Tablet: 2.2 hours (range: 1 to 3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (57% to 78%; 5% to 8% as metabolites); feces (8% to 30%) within 10 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524681\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Megace ES Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">625 mg/5 mL (150 mL): $1,205.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Megestrol Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (240 mL): $143.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">625 mg/5 mL (150 mL): $898.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Megestrol Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $69.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $123.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192303\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apegestrol (BD);</li>\n      <li>Apetrol (KR);</li>\n      <li>Endace (IN);</li>\n      <li>Maygace (ES);</li>\n      <li>Megace (AR, AT, AU, BD, BE, BG, CL, CN, CO, CZ, DK, EE, EG, FR, GB, GR, HK, HN, HR, IE, IT, JO, JP, KR, KW, LB, LT, LU, MY, NL, NO, NZ, PK, PL, PT, QA, RU, SA, SG, SI, TH, TR, TW, UY, VN);</li>\n      <li>Megace ES (BB);</li>\n      <li>Megace Oral (BB);</li>\n      <li>Megaplex (ID, PH, RU, TH);</li>\n      <li>Megase (VE);</li>\n      <li>Megastrol (PY);</li>\n      <li>Megatus (TW);</li>\n      <li>Megejohn (TW);</li>\n      <li>Megesia (KR);</li>\n      <li>Megesin (HK, RO);</li>\n      <li>Megestat (BR, DE);</li>\n      <li>Megex-I (PE);</li>\n      <li>Megostat (AU, HR);</li>\n      <li>Mestrel (MX, TH);</li>\n      <li>Mestrol (TW);</li>\n      <li>Norea (ES);</li>\n      <li>Onistrol (LK);</li>\n      <li>Tracetate (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azcona C, Castro L, Crespo E, Jim&eacute;nez M, Sierrases&uacute;maga L. Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours. <i>Aliment Pharmacol Ther</i>. 1996;10(4):577-586.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/8853762/pubmed\" target=\"_blank\" id=\"8853762\">8853762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brady MT, Koranyi KI, Hunkler JA. Megestrol acetate for treatment of anorexia associated with human immunodeficiency virus infection in children. <i>Pediatr Infect Dis J</i>. 1994;13(8):754-756.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/7970985/pubmed\" target=\"_blank\" id=\"7970985\">7970985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. <i>Pediatrics</i>. 1997;99(3):354-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/9041287/pubmed\" target=\"_blank\" id=\"9041287\">9041287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuvelier GD, Baker TJ, Peddie EF, et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. <i>Pediatr Blood Cancer</i>. 2014;61(4):672-679.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/24167059/pubmed\" target=\"_blank\" id=\"24167059\">24167059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eubanks V, Koppersmith N, Wooldridge N, et al, &ldquo;Effects of Megestrol Acetate on Weight Gain, Body Composition, and Pulmonary Function in Patients With Cystic Fibrosis,&rdquo; <i>J Pediatr</i>, 2002, 140(4):439-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/12006958 /pubmed\" target=\"_blank\" id=\"12006958 \">12006958 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hobbs DJ, Bunchman TE, Weismantel DP, et al. Megestrol acetate improves weight gain in pediatric patients with chronic kidney disease. <i>J Ren Nutr</i>. 2010;20(6):408-413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/20430646/pubmed\" target=\"_blank\" id=\"20430646\">20430646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Winkler M. Decompensated septic shock in the setting of megace-induced severe adrenal suppression in an otherwise healthy pediatric patient: a case report. <i>Pediatr Emerg Care</i>. 2012;28(8):802-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/22863821/pubmed\" target=\"_blank\" id=\"22863821\">22863821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. <i>J Pediatr Gastroenterol Nutr</i>. 2000;31(3):264-269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/10997370/pubmed\" target=\"_blank\" id=\"10997370\">10997370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megace ES (megestrol acetate) [prescribing information]. Spring Valley, NY: Par Pharmaceuticals Companies, Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megace (megestrol acetate oral suspension) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Megestrol tablets [prescribing information]. Columbus, OH: Roxane Laboratories; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nasr SZ, Hurwitz ME, Brown RW, et al, &ldquo;Treatment of Anorexia and Weight Loss With Megestrol Acetate in Patients With Cystic Fibrosis,&rdquo; <i>Pediatr Pulmonol</i>, 1999, 28(5):380-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/10536070/pubmed\" target=\"_blank\" id=\"10536070\">10536070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson S, Nygren KG, Johansson ED. Megestrol acetate concentrations in plasma and milk during administration of an oral contraceptive containing 4 mg megestrol acetate to nursing women. <i>Contraception</i>. 1977;16(6):615-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/606501/pubmed\" target=\"_blank\" id=\"606501\">606501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orme LM, Bond JD, Humphrey MS, et al. Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. <i>Cancer</i>. 2003;98(2):397-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/12872362/pubmed\" target=\"_blank\" id=\"12872362\">12872362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stockheim JA, Daaboul JJ, Yogev R, et al, &ldquo;Adrenal Suppression in Children With the Human Immunodeficiency Virus Treated With Megestrol Acetate,&rdquo; <i>J Pediatr</i>, 1999, 134(3):368-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/megestrol-acetate-pediatric-drug-information/abstract-text/ 10064680 /pubmed\" target=\"_blank\" id=\" 10064680 \"> 10064680 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12578 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192314\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F192315\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060125\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060118\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192294\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F192278\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060128\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132799\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F192309\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060127\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F192337\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192335\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192282\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299657\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192287\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192290\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4627707\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060124\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192281\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F192300\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524681\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192303\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12578|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=megestrol-acetate-drug-information\" class=\"drug drug_general\">Megestrol acetate: Drug information</a></li><li><a href=\"topic.htm?path=megestrol-acetate-patient-drug-information\" class=\"drug drug_patient\">Megestrol acetate: Patient drug information</a></li></ul></div></div>","javascript":null}